2 results on atopic dermatitis
Approved WMORecruiting
The objective of this phase III study is to evaluate the efficacy and safety of Tozorakimab according to 300 mg every 8 weeks (Q8W) and 300 mg every 4 weeks (Q4W) dosing regimens administered in adult participants with symptomatic COPD and a history…
Approved WMOCompleted
* To evaluate the effects of topically applied erythromycin and clindamycin in patients with facial AV* To explore skin and faecal microbiota in patients with AV;* To evaluate the effects of topically applied erythromycin and clindamycin on skin and…